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Bacterinsa b s t r a c t
Enzootic Pneumonia (EP) caused by Mycoplasma hyopneumoniae results in major economic losses to the
swine industry. Hence, the identification of factors that provide protection against EP could help to
develop effective vaccines. One such factor that provides partial protection are bacterins. Therefore,
the aim of this study was to verify the induction of antibodies against fifteenM. hyopneumoniae antigens,
strongly recognized by the swine immune system during natural infection, in mice vaccinated with six
commercial bacterins. Each group of mice was inoculated with one bacterin, and seroconversion was
assessed by indirect ELISA using recombinant antigens and M. hyopneumoniae 7448 whole cell extract.
Sera from one inoculated group recognized antigen MHP_0067, and sera from four inoculated groups rec-
ognized antigens MHP_0513 and MHP_0580. None of the bacterins was able to induce seroconversion
against the twelve remaining antigens. This absence of a serological response could be attributed to
the lack of antigen expression in M. hyopneumoniae strains used in bacterin production. Additionally
the partial protection provided by these vaccines could be due to low expression or misfolding of antigens
during vaccine preparation. Therefore, the supplementation of bacterins with these recombinant antigens
could be a potential alternative in the development of more effective vaccines.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Enzootic Pneumonia (EP) is a worldwide disease that results in
major economic losses to the swine industry [1]. Commercial
vaccines, which consists of inactivated whole-cell adjuvanted for-
mulations (bacterins), induce partial protection against EP [2,3].These vaccines provide protection by reducing lung damage, clini-
cal signs and weight loss and improving production rates in vacci-
nated animals [4–7]. Although the partial protective mechanisms
have not been fully elucidated, it has been described that these
bacterins are able to induce both local and systemic immune
responses [8–10]. However, they are not capable of avoiding trans-
mission of the pathogen [11,12]. Therefore, identification of the
factors that mediate the partial protection of bacterins can enable
the development of highly effective vaccines against EP.
Comparative analysis of Mycoplasma hyopneumoniae strains
allowed the identification of virulence factors possibly related to
bacterial pathogenesis [13–16]. Previous work has shown that
commercial bacterins did not induce antibodies against P97
adhesin and NrdF protein [17–20], virulence factors well character-
ized that were capable of promoting some level of protection in
swine subjected to experimental challenge conditions [21–24].
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studies from our group also demonstrated that one commercial
bacterin did not induce antibodies in mice against severalM. hyop-
neumoniae surface antigens [19,20,25,26]. Hence in order to better
understand the bacterins and their protective mechanisms, it is
essential to investigate the profile of antibodies generated by these
formulations. Therefore, the aim of this study was to verify the
induction of antibodies against fifteen M. hyopneumoniae antigens
in mice vaccinated with six commercial bacterins. These antigens
were selected based on our previous studies that demonstrated
their ability to be strongly recognized by swine immune system
during M. hyopneumoniae natural infection [20,25–27].2. Materials and methods
2.1. Commercial vaccines
Six commercial bacterins against EP were used in this study:
Ingelvac Mycoflex (Boehringer Ingelheim; 008/10), M+Pac
(Intervet; 00051097 023/11), Mypravac Suis (Hypra, 15FH-1
002/11), Respisure 1One (Pfizer, 002/2011), ResprotekTM One Shot
(Bayer, 002/2012) and Serkel Pneumo (Vencofarma, 002/2010).
These bacterins were randomly designed as A–F.
2.2. Selection and production of recombinant antigens
Fifteen proteins with probability of being virulence factors were
selected from the M. hyopneumoniae 7448 database (GenBank,
NC_007332.1) [14]. The following criteria were used for candidate
protein selection: (i) likelihood of being a virulence factor based on
genomic and proteomic comparative analysis between virulent
and avirulentM. hyopneumoniae strains [14–16]; (ii) predicted cel-
lular localization on the outer cell surface (transmembrane or
secreted protein) [25,27]; (iii) high antigenicity [25,26]; (iv) high
immunogenicity in mice [25,26]; (v) significant probability of hav-
ing adhesin activity relative to the protein MHP_0198 (P97 adhe-
sin) according to the analisis from Vaxign software [28]. The
recombinant proteins corresponding to the fifteen selected anti-
gens were produced according to Simionatto et al. [27].
2.3. Swine sera
Three pools of positive and negative swine sera (three sera/
pool) were used to confirm antigenicity of recombinant antigens
and as ELISA controls. Positive swine sera were obtained from ani-
mals aged approximately 3 months old, unvaccinated against EP,
and positive diagnosis of EP. This diagnosis was based on clinical
signs, positive serology assessed by indirect ELISA with crude
extract of M. hyopneumoniae strain 7448 [27] and positive PCR
from nasal swab [29]. Negative sera were obtained from a swine
herd tested to be free from M. hyopneumoniae infection through
PCR and serology.
2.4. Mice inoculation
Male BALB/c mice aged 6–8 weeks old (5 mouse/group) were
immunized with commercial vaccines (one bacterin/group) or
saline without adjuvant (100 ll) as negative control, via intramus-
cular injection. The mice received 5% of the dose recommended by
the manufacturer for swine. When indicated, each animal was
boosted with the same dose 21 days after the first innoculation.
Blood samples were collected from the retro-orbital sinus at days
0 and 42 after first innoculation. At day 42, the animals were euth-
anized. All animal experiments were performed according to the
guidelines of the Ethics Committee in Animal Experimentationfrom the Federal University of Pelotas (project number 7722).
The experiment was repeated twice.2.5. Assessment of humoral immune response
Seroconversion of mice was evaluated through indirect ELISA
using recombinant antigens or M. hyopneumoniae 7448 whole cell
extract. A previous analysis was performed to determine the opti-
mum amount of antigens (100 ng, 300 ng, 500 ng, 750 ng or 1 lg)
to coat the plate and the mice sera diluition (1:25, 1:50, 1:100 or
1:200) to be used in the analysis. The antigen amount which
resulted in highest reactivity before reaching the plateau, and the
lowest sera diluition with no detection of background (detectable
reactivity against negative sera) were selected to perform the
ELISA. Microtiter plates were coated with recombinant antigens
or with crude extract of M. hyopneumoniae strain 7448 (500 ng/
well) diluted in 50 mM carbonate–bicarbonate (pH 9.6) and incu-
bated overnight at 4 C. Wells were washed three times with
phosphate-buffered saline + 0.05% Tween 20 (PBS-T) and incubated
for 2 h at 37 C with 5% non-fat dry milk diluted in PBS (blocking
solution). After three washes, wells were incubated for 2 h at
37 C with mice or swine sera (1:50) diluted in blocking solution.
After three washes, wells were incubated for 1 h and 30 min at
37 C with goat IgG anti-mouse antibody (1:6000) or rabbit IgG
anti-pig (1:4000) conjugated to horseradish peroxidase (Sigma
Aldrich) diluted in PBS. Reaction was developed with
o-phenylenediamine dihydrochloride (Sigma Aldrich) and hydro-
gen peroxide, after PBS-T washes. The color reaction was allowed
to develop for 15 min and stopped with 50 lL of 2 M H2SO4. Absor-
bance was determined at 492 nm with plate reader ThermoPlate
ELX800 (BioTek Instruments). The mean and standard deviation
(S.D.) values for animal samples were calculated. Reactions were
preformed in triplicate. Values of seroconversion were obtained
by the quotient between the average absorbance of immune sera
and non-immune sera (O.D. day 42/O.D. day 0 for mice and O.D.
positive sera/O.D. negative sera for swine). Seroconversion was
considered positive when increased four times.2.6. Statistical analysis
GraphPad Prism 4 software systems (GraphPad Software) was
used to perform the statistical analysis and build the graphics.
Seroconversion data were submitted to ANOVA followed by Dun-
nett test to determine significant differences (C.I. 95%, p < 0.05)
between sera of mice inoculated with the bacterins and the nega-
tive control. Unpaired Student t Test was used to determine signif-
icant difference between positive and negative swine sera.3. Results
3.1. Recombinant antigen selection
According to the previously stipulated criteria, fifteen recombi-
nant antigens were selected for this study (Table 1). The antigens
MHP_0067, MHP_0223 and MHP_0596 do not have predicted
adhesin activity. To confirm the antigenicity of these recombinant
antigens, their reactivity with positive and negative swine sera was
evaluated by ELISA. All recombinant antigens were strongly recog-
nized by positive swine sera (p < 0.05) (Table 2), supporting our
previous characterization demonstrating that recombinant anti-
gens maintain reactive epitopes similar to those found in native
proteins [25,26].
Table 1
Identification and characterization of recombinant antigens selected.
Annotation Identification Selected
fragment (aa)
Molecular
mass (kDa)
Antigenicity with pig sera1
ELISA*/western blot**
Immunogenicity in
mice1 ELISA***
Likely location in
cell 2
Likely adhesin
activity (%)2
1 MHP_0067 DnaK chaperone 229–601 42 +/HC + Cytoplasm (99.7%) 18.7
2 MHP_0099 P95 564–911 43 +/C + Outer membrane
(94.9%)
55.8
3 MHP_0107 P1023 648–948 38 +/C + Outer membrane
(95.2%)
52.6
4 MHP_0223 NrdF beta chain 202–340 14 +/NR + Cytoplasmic
(89.6%)
19.2
5 MHP_0234 Periplasmic sugar
binding
12–340 39 +/HC + Unknown 52.8
6 MHP_0272 P973 228–708 59 +/C + Outer membrane
(94.9%)
43.4
7 MHP_0332 Subtilisin-like
serine protease
58–264 25 +/CϮ + Outer membrane
(94.9%)
43.6
8 MHP_0372 LppT protein 497–883 44 +/C + Outer membrane
(94.9%)
54.5
9 MHP_0373 LppS protein 776–982 27 +/H + Unknown 42.6
10 MHP_0390 Hypothetical
protein
4–214 26 +/HC + Cytoplasmic
Membrane (100%)
54.2
11 MHP_0468 Hypothetical
protein
118–467 42 +/NR + Cytoplasm (89.6%) 60.5
12 MHP_0513 P46 102–420 35 +/C + Periplasm (97.6%) 40.3
13 MHP_0580 Membrane
nuclease
lipoprotein
180–378 25 +/C + Unknown 57.7
14 MHP_0596 Hypothetical
protein
110–379 31 +/CϮ + Outer membrane
(94.9%)
21.3
15 MHP_0663 P146 754–1022 30 +/NR + Outer membrane
(95.2%)
53.1
1 Data obtained from previous work of our research group [25,26].
2 Likely location in cell and significant probability of having adhesin activity, determined by Vaxign [28] online software; probability values for adhesin activity were
considered positive when near or above the value predicted for the characterized adhesin MHP_0198 (P97), 49.1%.
3 Paralog protein.
* ELISA of recombinant proteins against convalescent and SPF swine sera; + recombinant antigens that presented positive reaction with convalescent swine sera, with
significant statistical differences compared to SPF sera (p < 0.05).
** Western blot of recombinant proteins against swine sera from SPF, convalescent and swine immunized with M. hyopneumoniae 7448 inactivated whole cell; H,
recombinant proteins recognized by hyperimmune sera; C, recombinant proteins recognized by convalescent sera; HC, recombinant proteins recognized by both, hyper-
immune and convalescent; CϮ, recombinant proteins recognized by convalescent sera, but not tested against hyperimmune sera; NR, recombinant proteins with no reaction
against convalescent or hyperimmune sera.
*** ELISA of recombinant proteins against sera from immunized mice; + recombinant antigens that presented positive reaction with immunized sera, with significant
statistical differences compared to non-immunized (saline) sera (p < 0.05).
Table 2
Mean and standard deviation of absorbance related to the reactivity of the negative
control swine serum (CS) and positive (CS+) with the selected recombinant antigens
and the M. hyopneumoniae extract 7448.
Antigens CS CS+ p
MHP_0067 0.336 ± 0.013 3.269 ± 0.112 <0.0001
MHP_0099 0.179 ± 0.019 1.366 ± 0.152 0.0003
MHP_0107 0.218 ± 0.021 1.477 ± 0.259 0.0011
MHP_0223 0.313 ± 0.014 1.269 ± 0.114 0.0006
MHP_0234 0.262 ± 0.029 1.161 ± 0.097 0.0001
MHP_0272 0.247 ± 0.015 1.024 ± 0.020 0.0005
MHP_0332 0.291 ± 0.015 1.193 ± 0.279 0.04
MHP_0372 0.415 ± 0.015 2.813 ± 0.148 <0.0001
MHP_0373 0.260 ± 0.039 1.395 ± 0.404 0.0085
MHP_0390 0.252 ± 0.020 1.586 ± 0.295 0.0015
MHP_0468 0.256 ± 0.026 1.763 ± 0.212 0.0003
MHP_0513 0.428 ± 0.017 2.596 ± 0.429 0.0009
MHP_0580 0.313 ± 0.008 1.291 ± 0.060 <0.0001
MHP_0596 0.360 ± 0.007 1.456 ± 0.342 0.0052
MHP_0663 0.210 ± 0.022 1.668 ± 0.208 0.0003
M. hyopneumoniae 7448 0.425 ± 0.011 3.232 ± 0.247 <0.0001
Fig. 1. Mean seroconversion of sera from mice inoculated with bacterins or saline,
determined by indirect ELISA using M. hyopneumoniae 7448 whole cell extract as
antigen. The vertical bars correspond to the standard deviations of the seroconver-
sions. All reactions were performed in triplicate. Asterisks (⁄) indicate statistical
difference (p < 0.05) between seroconversion of mice inoculated with the bacterins
and the negative control group (saline), verified by ANOVA followed by Dunnett
test.
34 A. Fisch et al. / Trials in Vaccinology 5 (2016) 32–373.2. Humoral immune response induced by bacterins in mice
To confirm the immunogenicity of the evaluated bacterins, the
reactivity of sera from vaccinated mice against M. hyopneumoniae
7448 whole cell extract was assessed by ELISA. Except for bacterin
F, all other bacterins showed significant reactivity in this analysis,
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suggests failure of the vaccination with the bacterin F, this vaccine
induced significant seroconversion against one of the recombinant
antigens. Hence bacterin F was selected for use in this study.
Furthermore, only one of the six bacterins was able to induce
seroconversion against the antigen MHP_0067 (Fig. 2A), and four
bacterins induced seroconversion against the antigens MHP_0513Fig. 2. Mean seroconversion of sera from mice inoculated with bacterins or saline,
determined by indirect ELISA using MHP_0067 (A), MHP_0513 (B) or MHP_0580 (C)
as antigen. The vertical bars correspond to the standard deviations of the
seroconversions. All reactions were performed in triplicate. Asterisks (⁄) indicate
statistical difference (p < 0.05) between seroconversion of mice inoculated with the
bacterins and the negative control group (saline), verified by ANOVA followed by
Dunnett test.(Fig. 2B) and MHP_0580 (Fig. 2C). Moreover, all the bacterins failed
to induce seroconversion against the antigens MHP_0099,
MHP_0107, MHP_0223, MHP_0234, MHP_0272, MHP_0332,
MHP_0372, MHP_0373, MHP_0390, MHP_0468, MHP_0596 and
MHP_0663 (data not shown). Bacterin E failed to induce serocon-
version against all fifteen evaluated antigens.
4. Discussion
Based on the annotation of M. hyopneumoniae 7448 genome
[30], proteins possibly associated with the pathogenesis of this
bacteria and with high potential to be used as vaccines were iden-
tified. We cloned 71 of these candidate proteins, and 36 were suc-
cessfully produced in Escherichia coli, purified and characterized for
their antigenicity and immunogenicity [20,25,26]. Based on the ini-
tial characterization of these recombinant proteins, fifteen of these
antigens which play a role in host–pathogen interactions, such as
adhesion or tissue damage, and/or are strongly recognized by the
swine immune system during natural infection were selected for
further serological analysis. Since the commercially available bac-
terins result in partial protection against EP, we investigated their
ability to induce humoral immune response in mice against the
above mentioned 15 putative virulence factors of M. hyopneumo-
niae. Although the bacterins evaluated were able to induce anti-
bodies against the crude bacteria extract, they did not induce
seroconversion in mice against most of the selected antigens, sug-
gesting that the bacterial strains used to produce these vaccines do
not express them or that the vaccine preparation results in low
expression or misfolding of these antigens. Furthermore, the adju-
vants used in the formulation of commercial bacterins may not be
suitable for the presentation of these antigens in particular. This
result corroborates with findings of our previous studies, which
demonstrated that the commercial bacterin used as control during
experiments did not induce immune response against the antigens
evaluated at that time [20,25,26]. The absence, low expression or
misfolding of putative virulence factors in commercial bacterins,
as well as the inappropriate processing of these antigens by pre-
senting cell, could be related with the partial protection conferred
to the vaccinated swines against EP.
Conditions of in vitro growth modulate M. hyopneumoniae
expression profile. Mycoplasma hyopneumoniae 232 grown in vitro
showed changes in transcriptome profile when compared with
the same strain recovered after experimental in vivo infection in
pigs [31]. Assunção et al. [32] identified antigenic variation of
M. hyopneumoniae strains isolated from slaughterhouses according
to the number of in vitro passages. Bacterins are produced with
strains that suffer successive in vitro passages in optimal growing
conditions, which may lead to a reduction or interruption of the
gene expression required for natural infection, such as adhesins.
M. hyopneumoniae require adhesins to attach to respiratory tract
epithelial cilia, and antibodies capable of binding these adhesins
may decrease the establishment of bacteria in the host tissues
[33]. In a total of fifteen antigens evaluated in the present study,
twelve (about 80%) were highly likely to have adhesin activity
according to bioinformatic prediction. It is worth noting that none
of the bacterins induced detectable levels of antibody against pro-
teins P97 (MHP_0272) and P146 (MHP_0663), which are confirmed
adhesin of M. hyopneumoniae [33–36]. Since most bacterins evalu-
ated in this study are produced with avirulent J strain of M. hyop-
neumoniae, the results of this study also corroborate the findings of
Li et al. [16], which showed through proteomic analysis that J
strain has lower expression of genes associated with the synthesis
of adhesins when compared to 232 strain. Absence or low expres-
sion of adhesins by vaccine strains may compromise neutralizing
antibody induction and reduce vaccine efficacy, thereby allowing
M. hyopneumoniae colonization and persistence in the host.
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research groups have investigated the use of attenuated strains
ofM. hyopneumoniae, but the results obtained so far are controver-
sial. Villarreal et al. [37] showed that infection with an isolate of
low virulence did not protect piglets challenged with a highly
virulent isolate. On the other hand, vaccines based on the attenu-
ated M. hyopneumoniae strain 168 administered by intrapulmonic
and intramuscular routes conferred significant protection against
experimental EP [38–40]. However, a comparison with an inacti-
vated vaccine (bacterin) was not performed. Regardless of the
effectiveness of this type of vaccine, it seems reasonable to hypoth-
esize that the same limitations of bacterins, demonstrated in the
present study, also occur in live attenuated vaccines, since they
are produced from strains that have been cultivated in vitro
through successive passages in culture medium. In fact, a compar-
ative genomic analysis between the attenuated and the virulent
variants of strain 168 showed the occurrence of mutations in
CDS of diverse virulence factors, including adhesins after attenua-
tion [41]. Many of the mutations identified generates truncated
CDS, but the direct effects of the mutations on the protein expres-
sion was not evaluated. Therefore, it is necessary to determine the
protein expression profile of virulence factors in attenuated strains
and the antibody induction after immunization, in order to clarify
whether the use of live attenuated vaccines could be a useful
approach when the objective is to enhance the immunity against
these antigens.
An alternative approach to improve vaccine efficacy is to
increase virulence factor expression during in vitro growth by sim-
ulating the host lung enviroment during natural infection [42–44].
Supplementation of the medium with norepinephrine induced
overexpression of some virulence genes of M. hyopneumoniae
strain 232, including the adhesin P146 [43]; while increasing the
incubation temperature of the culture promoted overexpression
of DnaK chaperone by the same strain [44]. In this study, all bac-
terins failed to stimulate production of anti-P146 antibodies
(MHP_0663) and only one of them stimulated the production of
anti-DnaK (MHP_0067) antibodies. This strategy may be useful
when the goal is to overexpress a few antigens; however, to induce
the expression of several virulence factors it may be critical to
provide different stimuli to bacteriale growth. In addition, the
determination of optimal conditions for in vitro stimulation is
dependent on further elucidation of the disease pathogenesis.
Thus, supplementation of bacterins with recombinant antigens
seems to be the best alternative to increase the level of protection
against EP.
Adjuvants are essential compounds in vaccines, capable of
enhance antigen processing and adaptative immune responses
[45]. It has been shown that the use of different adjuvant formula-
tions affects the immunogenicity and protective effect of attenu-
ated and inactivated wholle-cell M. hyopneumoniae vaccines.
[40,46]. Thus, evaluate the development of immune response
against specific virulence factors and their correlation with protec-
tion against EP after immunization with M. hyopneumoniae associ-
ated to different adjuvants is necessary to verify if this could be a
useful approach to enhance protection elicited by bacterins.
In this study we have demonstrated that commercial bacterins
failed to stimulate seroconversion in mice against M. hyopneumo-
niae antigens that were strongly recognized by the immune system
of pigs. This may be due to the low expression of these antigens
during in vitro bacterial cultivation. Therefore, the addition of
recombinant antigens to commercial bacterins could be a potential
alternative for development of effective vaccines. However, future
studies are necessary to evaluate the interactions between the
recombinant antigens and commercial vaccines and the protective
potential of these associations.Conflict of interest statement
The authors state they have no conflict of interest.
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